Business Wire

CA-INGRAM-MICRO

4.5.2021 14:05:12 CEST | Business Wire | Press release

Share
Ingram Micro Announces Global Relationship with Leading Enterprise Automation Software Company UiPath

Growing its Artificial Intelligence (AI) portfolio, Ingram Micro Inc. today announced an expanded, and now global, business relationship with UiPath , a leading enterprise automation software company and Robotic Process Automation (RPA) tech innovator.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504005476/en/

RPA enables organizations in the digital transformation (DX) era to increase efficiency, workflow determinism, operation accuracy and compliance with regulations by automating repetitive and time-consuming mundane tasks. Additionally, software robots work to establish end-to-end automation across the organization while driving costs down. Ingram Micro’s broad and specialized Advanced Solutions portfolio began offering AI and RPA solutions a few years ago and has become one of the organization’s fastest-growing global practices.

“Robotic process automation is an important component within a company’s digital transformation game plan, and a great sales wedge for channel partners to introduce DX solutions and services into their existing end user customer base,” said Sabine Howest, vice president, global partner engagement and IoT, Ingram Micro Inc. “Using AI to automate repeatable, rules-driven processes is a practice companies of all sizes can benefit from and a growth opportunity we’re ready to drive with UiPath through our growing and global Advanced Solutions organization.”

“We’re thrilled that UiPath is offering additional support to high-value service providers like us through its new Ingram Micro program,” said Bhavyesh Virani, co-CEO of WonderBotz, a UiPath partner. “Ingram Micro’s global reach will help WonderBotz capture the rising demand for our custom services as well as for our prebuilt turnkey solutions for F&A professionals and healthcare, finance, banking, and hospitality leaders. The new UiPath/Ingram Micro program is an all-around win, enabling us to spend more time on delivering industry-leading client services.”

Ingram Micro’s relationship with UiPath started in India in 2018 and was quickly followed by China. Currently, the relationship is now expanded to North America and Latin America as well as Europe, Middle East, Africa, and the remainder of Asia Pacific. The team at Ingram Micro maintains a mature and dedicated UiPath team of experts who are here to help channel partners throughout the sales cycle including opportunity identification, design thinking, advisory services, licensing and training. With the support of Ingram Micro’s Centers of Excellence, channel partners selling UiPath benefit from shared best practices, “follow the sun” support services and global resources designed to meet the varied demands of the market locally, regionally, and globally.

“Ingram Micro and UiPath are partner-first organizations equally committed to continually investing in our partners to drive greater service differentiation, exceptional growth, and improved profitability,” says Thomas Hansen, Chief Revenue Officer, UiPath. “Enterprise automation is a category channel partners cannot ignore, and an investment enterprise organizations are making because of the immediate and measurable return on investment and improvement to the associate experience and the customer experience. We are thrilled to expand our successful relationship with Ingram Micro worldwide and look forward to helping channel partners capitalize on the market potential for RPA.”

In Q1 2021, the Forrester Wave™*: Robotic Process Automation named UiPath “a Leader” with the highest ranking in each of three categories: Current Offering, Strategy, and Market Presence. Additionally, UiPath Vice President of Global Alliances and Partners, Cheryln Chin, and Senior Vice President of Operations and Partners, Eddie O’Brien were recently named to the 2021 CRN Channel Chiefs list, along with eight Ingram Micro channel executives.

The entire UiPath portfolio is now available to Ingram Micro channel partners worldwide. To learn more about UiPath, contact your Ingram Micro partner manager. For Quote to order support, please email: UiPath-licensing@ingrammicro.com and for sales and pre-sales support, please email: UiPath-sd@ingrammicro.com .

*The Forrester Wave™: Robotic Process Automation, Q1 2021, March 15, 2021

About UiPath

UiPath has a vision to deliver the Fully Automated Enterprise™, one where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.

About Ingram Micro

Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/IngramMicroLatinAmericaDivision

https://www.facebook.com/IngramTechSol

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye